Clinical trials: Patients With Type 2 Diabetes
Severe Complications of Urinary Tract Infections
Complications of UTI in Patients on Dapagliflozin
The objective of this study is to compare, by insulin use at the index date, the sex-specific incidence of hospitalization or emergency department (ED) visit for severe complications of urinary tract infections (UTI), defined as…
- Trial name
- NCT02695173
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 683,380 people
- Sponsor
- AstraZeneca
Erectile Dysfunction
Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patients With Diabetes.
Sixty diabetes men with erectile dysfunction from mild to severe who agree to participate is going to have medical care approximately for 16 weeks.
- Trial name
- NCT01180283
- Testing
- lodenafil carbonate
- Where
- 3 sites in Brazil
- Sponsor
- Cristália Produtos Químicos Farmacêuticos Ltda.
Heart Failure
Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone
This study will be conducted in subjects with clinical diagnosis of worsening chronic heart failure and either type 2 diabetes mellitus (DM) with or without chronic kidney disease (CKD) or moderate CKD alone treated with…
- Trial name
- ARTS-HF Japan (NCT01955694)
- Testing
- BAY94-8862, Eplerenone
- Where
- 29 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Diabetes Mellitus Type 2
Lispro Mix 25 vs. Glargine in Type 2 Diabetics
In patients with type 2 diabetes who have not been on insulin therapy before the study will achieve better glycemic control by the treatment regiment consisting of two times daily insulin lispro mix 25 than by the treatment…
- Trial name
- IOOL (NCT00551356)
- Testing
- Insulin lispro mix 25, Glargine
- Where
- Mexico
- Volunteers
- 53 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Primary Objective: To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24.
- Trial name
- BRIGHT (NCT02738151)
- Testing
- Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
- Where
- 158 sites in United States, Bulgaria and 14 more
- Volunteers
- 929 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in…
- Trial name
- NCT01194245
- Testing
- Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart
- Where
- 19 sites in United States
- Volunteers
- 135 people
- Sponsor
- Halozyme Therapeutics
Diabetes, Diabetes Mellitus, Type 2
An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients
This study is conducted in Asia. The aim of this observational study is, under normal clinical practice conditions, to investigate the clinical safety and effectiveness in Chinese patients with type 2 diabetes who have never…
- Trial name
- SAFE (NCT01077570)
- Testing
- repaglinide
- Where
- China
- Volunteers
- 2,033 people
- Sponsor
- Novo Nordisk A/S
Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis
A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
This is a randomized, double-blind study of MSDC-0602K or placebo in subjects with pre-T2D or T2D and evidence of NAFLD/NASH.
- Conditions
- Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03970031
- Testing
- MSDC-0602K
- Volunteers
- 1,800 people
- Sponsor
- Cirius Therapeutics, Inc.
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
This trial is conducted in the United States of America (USA). The aim of the trial is to confirm the efficacy of IDeg (insulin degludec) versus IGlar (insulin glargine) in controlling glycaemia.
- Trial name
- NCT01570751
- Testing
- insulin degludec, insulin glargine
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 145 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy
The study will be conducted in participants with type 2 diabetes on insulin injection therapy to investigate how the body processes LY900014 and the effect of LY900014 on blood sugar levels.
- Trial name
- NCT02703337
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of LY3305677 in Participants With Type 2 Diabetes
The main purpose of this study is to learn more about the safety and side effects of LY3305677 when it is given as an injection just under the skin to participants with type 2 diabetes.
- Trial name
- NCT03928379
- Testing
- LY3305677
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes
This trial is conducted in Europe. The objective of the study is to investigate the effect and safety of continously basal delivered insulin aspart given by a pump versus once daily injection of insulin glargine.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00184613
- Testing
- pump, insulin glargine, insulin aspart
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
This surveillance is a postmarketing commitment following the marketing authorization for Forxiga(dapagliflozin) in accordance with Standards on Re-examination of New Drugs, notified by the MFDS under Article 32, Paragraph 1 and…
- Trial name
- NCT02252224
- Where
- 6 sites in South Korea
- Volunteers
- 3,123 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.
This study was aimed to achieve of long-term weight loss in T2DM patients by use of comprehensive lifestyle changes program, providing patients with structured diet, exercise plan, group behavioral support and group education.
- Trial name
- NCT02670928
- Testing
- Lifestyle intervention
- Where
- 2 sites in Russia
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Hypertriglyceridemia, Type 2 Diabetes
Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
To assess the efficacy and safety of orally administered Epeleuton capsules versus placebo, in the treatment of adult patients with hypertriglyceridemia and type 2 diabetes
- Trial name
- TRIAGE (NCT04365400)
- Testing
- DS102
- Where
- 56 sites in United States, Georgia and 4 more
- Volunteers
- 233 people
- Sponsor
- Afimmune
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
The purpose of this study is to assess the efficacy of omarigliptin 25 mg weekly (as monotherapy) compared with sitagliptin 50 mg daily and placebo, and the long term safety (up to 52 weeks) of omarigliptin 25 mg weekly.
- Trial name
- NCT01703221
- Testing
- Omarigliptin, Sitagliptin
- Volunteers
- 414 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type II
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
The purpose of the study was to compare Humalog (insulin lispro)-recombinant human hyaluronidase PH20 (rHuPH20) or Novolog (insulin aspart)-rHuPH20 to insulin lispro for the treatment of Type 2 diabetes mellitus (T2DM) in…
- Trial name
- NCT01194258
- Testing
- Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20
- Where
- 22 sites in United States
- Volunteers
- 132 people
- Sponsor
- Halozyme Therapeutics
Type 2 Diabetes, Chronic Kidney Disease (CKD) Stages G2 to G3b
A Study to Learn More About How Well Finerenone Works in Real-world in People With Type 2 Diabetes and Chronic Kidney Disease in Primary Care (IMSS= Instituto Mexicano Del Seguro Social)
The main purpose of this study is to learn how treatment with finerenone affects the urinary albumin-to-creatinine ratio (uACR), a marker of kidney health, over time in adults with type 2 diabetes and chronic kidney disease who…
- Trial name
- FINE-IMSS-MX (NCT07841015)
- Testing
- Finerenone
- Where
- Mexico
- Volunteers
- 800 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes
The purpose of this study is to assess the long term safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who…
- Trial name
- NCT00120536
- Testing
- vildagliptin
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- Novartis
Diabetes, Diabetes Mellitus, Type 2
Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes
This study is conducted in Europe. The aim of this study is to evaluate the safety and efficacy of biphasic insulin aspart (NovoMix® 30) in hospitalised patients with type 2 diabetes with the aim of intensifying their treatment.
- Trial name
- NCT01565733
- Testing
- biphasic insulin aspart 30
- Where
- Poland
- Volunteers
- 2,223 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.